COVID-19 Website statement (19.03.2020 003)

We would like to provide reassurance that Fresenius Kabi UK and Calea are following all government guidelines regarding the evolving situation with COVID-19, and our companies have robust plans in place to support the service we provide to our customers and patients.

In line with Public Health England’s objective to minimise the risk and spread of COVID-19 [add link], we have communicated to all staff members the importance of good hygiene and sanitisation practices, the signs and symptoms of COVID-19, as well as self-isolation and quarantine measures they may need to observe.

Directives relating to travel and general health and safety to protect staff, their families and our patients are in place.  International travel has been suspended and attendance at exhibitions, congresses and large meetings has been cancelled. Non-critical business in hospitals has ceased with immediate effect.  Screening, risk assessment and reporting protocols are in place for any staff members that have been abroad or are due to travel.

Contingencies are in place for our nursing and delivery service to care for our patients in the community and to support hospital clinical teams with essential training, medical device maintenance and customer care.

As COVID-19 and government guidance continues to develop, Fresenius Kabi and Calea are monitoring the situation daily and the health, safety and well-being of our patients and employees remains our top priority.

We will continue to monitor the impact of any government-imposed self-isolation and quarantine restrictions on the availability of our staff, on logistics and the supply of products to patients and hospitals.

For further information and advice on the COVID-19 situation visit the NHS website [].

HPN Homecare team call: 0800 121 8300
Biosimilars Homecare team call: 0800 090 2461